Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

KYMR

Kymera Therapeutics Inc

Dec 04 • 04:00PM ET

46.02

Dollar change -0.89
Percentage change -1.90	%

Healthcare • Biotechnology • USA • NASD

Peers: SRRK NRIX ARDX QURE KPTI CRNC RVNC MREO ONCT

| Held by: VTI IWM VB XBI VXF VBK IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.33	Insider Own	15.30%	Shs Outstand	64.75M	Perf Week	0.09%
Market Cap	2.98B	Forward P/E	-	EPS next Y	-3.13	Insider Trans	-5.26%	Shs Float	54.85M	Perf Month	-2.23%
Income	-167.47M	PEG	-	EPS next Q	-0.77	Inst Own	93.75%	Short Float	16.63%	Perf Quarter	-1.24%
Sales	87.56M	P/S	34.04	EPS this Y	-11.46%	Inst Trans	4.46%	Short Ratio	21.60	Perf Half Y	35.87%
Book/sh	13.79	P/B	3.34	EPS next Y	-11.46%	ROA	-21.10%	Short Interest	9.12M	Perf Year	116.36%
Cash/sh	8.49	P/C	5.42	EPS next 5Y	1.90%	ROE	-26.00%	52W Range	20.32 - 53.27	Perf YTD	80.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.18%	ROI	-17.30%	52W High	-13.61%	Beta	2.17
Dividend TTM	-	Quick Ratio	8.55	Sales past 5Y	241.22%	Gross Margin	92.85%	52W Low	126.48%	ATR (14)	2.31
Dividend Ex-Date	-	Current Ratio	8.55	EPS Y/Y TTM	19.04%	Oper. Margin	-223.00%	RSI (14)	48.33	Volatility	3.48% 5.00%
Employees	187	Debt/Eq	0.10	Sales Y/Y TTM	86.92%	Profit Margin	-191.26%	Recom	1.44	Target Price	58.88
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	9.29%	Payout	-	Rel Volume	0.88	Prev Close	46.91
Sales Surprise	-63.81%	EPS Surprise	1.48%	Sales Q/Q	-20.88%	Earnings	Oct 31 BMO	Avg Volume	422.28K	Price	46.02
SMA20	-1.44%	SMA50	-1.32%	SMA200	11.45%	Trades		Volume	373,524	Change	-1.90%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$57
Nov-18-24	Initiated	Stephens	Overweight	$65
Sep-09-24	Resumed	Leerink Partners	Outperform	$60
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$65
Apr-22-24	Initiated	Oppenheimer	Outperform	$53
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $30
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$26
Jun-30-23	Initiated	Truist	Buy	$50
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $32
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy	$40
Aug-03-22	Initiated	Goldman	Buy	$40
Jul-20-22	Initiated	SVB Leerink	Mkt Perform	$26
Apr-28-22	Initiated	Credit Suisse	Outperform	$63
Mar-10-22	Initiated	JP Morgan	Neutral	$44
Feb-10-22	Initiated	Wells Fargo	Overweight	$62
Sep-30-21	Initiated	Stifel	Buy	$80

Show Previous Ratings

Nov-26-24 07:00AM	Kymera Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-05-24 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-24 03:07AM	Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 08:40AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Loading…
07:30AM	Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-30-24 09:10AM	Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-24-24 10:01AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
07:00AM	Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases (GlobeNewswire)
Oct-23-24 07:15AM	Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium (GlobeNewswire)
Oct-09-24 07:00AM	Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Sep-25-24 07:00AM	Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress (GlobeNewswire)
Sep-06-24 11:31AM	Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report? (Zacks)
Aug-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
11:15AM	Loading…
Aug-21-24 11:15AM	Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-24 01:02PM	Kymera (KYMR) to Raise $225 Million Through Offering of Shares (Zacks)
07:44AM	Avidity, Kymera raise fresh funds; Walgreens partners with BARDA (BioPharma Dive)
Aug-19-24 10:45PM	Kymera Therapeutics Announces Pricing of $225 Million Public Offering (GlobeNewswire)
04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Aug-08-24 09:55AM	Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-07-24 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-31-24 07:00AM	Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 (GlobeNewswire) +7.17%
Jul-10-24 08:10AM	Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains? (Zacks) -8.09%
Jul-09-24 01:30PM	Why Kymera Therapeutics Stock Is Soaring Today (Motley Fool) +23.40%
12:22PM	Kymera Therapeutics soars as Sanofi expands phase 2 trials (Investing.com)
10:44AM	Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug (Investopedia)
09:59AM	Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies (Zacks)
07:00AM	Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day (GlobeNewswire)
04:05PM	Loading…
Jul-08-24 04:05PM	Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy (GlobeNewswire) +5.65%
Jun-20-24 08:45AM	Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 (GlobeNewswire)
Jun-14-24 07:00AM	Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire)
Jun-01-24 08:00AM	Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting (GlobeNewswire)
May-29-24 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-23-24 05:00PM	Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting (GlobeNewswire)
May-22-24 11:20AM	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting (GlobeNewswire)
May-14-24 10:00AM	Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire) -8.52%
May-08-24 07:00AM	Kymera Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
May-03-24 12:23PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:57AM	Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
09:55AM	Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know (Zacks)
08:44AM	Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 (MT Newswires)
03:19AM	Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:18PM	Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises (MT Newswires)
11:57AM	KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) -5.28%
09:20AM	20 Counties with the Highest Cancer Rates in the US (Insider Monkey)
07:00AM	Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 (GlobeNewswire)
Apr-08-24 07:00AM	Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 10:00AM	Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-04-24 11:27PM	Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-23-24 11:59AM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 11:24PM	Q4 2023 Kymera Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:35AM	Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-21-24 11:52PM	Director Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-15-24 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22 (GlobeNewswire)
Feb-10-24 02:56AM	Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-31-24 07:00AM	Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference (GlobeNewswire)
Jan-24-24 12:20AM	Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-09-24 09:17AM	Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs (GlobeNewswire) +7.80%
09:15AM	Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-05-24 04:03PM	Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering (Investor's Business Daily)
06:00AM	Kymera Therapeutics Announces Pricing of $275 Million Public Offering (GlobeNewswire)
Jan-04-24 04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire) +18.86%
07:00AM	R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases (GlobeNewswire)
Jan-02-24 07:00AM	Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 (GlobeNewswire)
Dec-22-23 10:45AM	Kymera Therapeutics Has Doubled in 2 Months, But Is the Upside Sustainable? (TheStreet.com)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 07:00AM	Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4 (GlobeNewswire) +7.33%
Dec-10-23 09:00PM	Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-08-23 11:13AM	Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474 (Zacks)
Dec-07-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi (GlobeNewswire) +7.20%
Nov-13-23 11:00AM	Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine (GlobeNewswire)
Nov-07-23 09:05AM	BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc (GuruFocus.com) +13.61%
Nov-05-23 02:38PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 09:00AM	Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting (GlobeNewswire)
08:43AM	Kymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-27-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi (GlobeNewswire)
Oct-26-23 10:02AM	Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know (Zacks)
07:00AM	Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2 (GlobeNewswire)
Oct-19-23 09:35AM	Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-18-23 09:35AM	Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-16-23 07:00AM	Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma (GlobeNewswire)
Oct-04-23 06:23AM	Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks)
Oct-03-23 04:48PM	Why Shares of Kymera Therapeutics Jumped on Tuesday (Motley Fool) +14.30%
Sep-18-23 07:00AM	Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma (GlobeNewswire)
Aug-28-23 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-03-23 08:25AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +11.07%
07:00AM	Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-27-23 07:00AM	Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3 (GlobeNewswire)
Jul-09-23 09:09AM	Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth (Simply Wall St.)

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Esposito Pamela	Director	Dec 02 '24	Option Exercise	29.55	2,500	73,875	2,500	Dec 02 07:50 PM
Esposito Pamela	Director	Dec 02 '24	Sale	49.00	2,500	122,500	0	Dec 02 07:50 PM
PAMELA ESPOSITO	Director	Dec 02 '24	Proposed Sale	46.85	2,500	117,125		Dec 02 04:41 PM
Esposito Pamela	Director	Sep 17 '24	Option Exercise	23.86	13,500	322,075	13,500	Sep 17 06:20 PM
Esposito Pamela	Director	Sep 17 '24	Sale	48.28	13,500	651,766	0	Sep 17 06:20 PM
PAMELA ESPOSITO	Director	Sep 17 '24	Proposed Sale	48.48	13,500	654,480		Sep 17 04:40 PM
Albers Jeffrey W.	Director	Aug 26 '24	Option Exercise	10.34	5,000	51,700	5,000	Aug 26 06:31 PM
Albers Jeffrey W.	Director	Aug 26 '24	Sale	49.10	5,000	245,508	0	Aug 26 06:31 PM
JOANNA HOROBIN	Director	Aug 26 '24	Proposed Sale	49.16	12,000	589,896		Aug 26 04:32 PM
JEFFREY ALBERS	Director	Aug 26 '24	Proposed Sale	47.78	5,000	238,900		Aug 26 04:25 PM
BAKER BROS. ADVISORS LP	Director	Aug 20 '24	Buy	46.41	1	46	5,516,986	Aug 22 04:03 PM
Gollob Jared	Chief Medical Officer	Jul 16 '24	Option Exercise	2.08	23,145	48,142	118,885	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 15 '24	Option Exercise	2.08	16,455	34,226	112,195	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 16 '24	Sale	45.81	23,145	1,060,218	95,470	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 15 '24	Sale	45.15	16,455	742,925	95,740	Jul 16 06:00 PM
Booth Bruce	Director	Jul 09 '24	Sale	38.21	453,960	17,346,919	723,246	Jul 09 05:15 PM
Mainolfi Nello	Chief Executive Officer	Jul 01 '24	Option Exercise	5.33	18,773	100,060	649,959	Jul 01 04:30 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 27 '24	Option Exercise	2.08	25,000	52,000	168,554	Jun 28 08:30 AM
Mainolfi Nello	Chief Executive Officer	Jun 18 '24	Option Exercise	2.08	14,413	29,979	631,186	Jun 20 08:30 AM
Booth Bruce	Director	Jun 12 '24	Sale	35.45	16,740	593,378	803,792	Jun 14 06:01 PM
Booth Bruce	Director	Jun 13 '24	Sale	34.98	10,200	356,796	802,022	Jun 14 06:01 PM
Horobin Joanna	Director	Jun 07 '24	Option Exercise	2.08	8,500	17,680	8,500	Jun 07 06:36 PM
Horobin Joanna	Director	Jun 07 '24	Sale	32.99	8,500	280,400	0	Jun 07 06:36 PM
Chadwick Jeremy G	Chief Operating Officer	May 23 '24	Sale	34.99	2,575	90,105	44,183	May 23 04:10 PM
Booth Bruce	Director	Mar 15 '24	Sale	40.46	71,764	2,903,336	806,697	Mar 15 07:23 PM
Booth Bruce	Director	Mar 14 '24	Sale	39.98	55,779	2,229,927	819,151	Mar 15 07:23 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	134,647	5,652,072	4,791,165	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	115,090	4,859,993	4,676,075	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	42,302	1,812,586	4,925,812	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	28,271	1,186,741	852,995	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	24,165	1,020,422	828,830	Mar 13 07:53 PM
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	8,882	380,562	881,266	Mar 13 07:53 PM
Booth Bruce	Director	Mar 12 '24	Sale	41.98	162,918	6,838,813	852,995	Mar 13 07:52 PM
Booth Bruce	Director	Mar 13 '24	Sale	42.23	139,255	5,880,415	828,830	Mar 13 07:52 PM
Booth Bruce	Director	Mar 11 '24	Sale	42.85	51,184	2,193,148	881,266	Mar 13 07:52 PM
Gollob Jared	Chief Medical Officer	Mar 04 '24	Sale	41.86	3,344	139,967	95,740	Mar 04 06:21 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 04 '24	Sale	41.86	3,934	164,664	142,351	Mar 04 06:12 PM
Albers Jeffrey W.	Director	Feb 21 '24	Option Exercise	10.34	4,385	45,341	4,385	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 20 '24	Option Exercise	10.34	615	6,359	615	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 21 '24	Sale	39.05	4,385	171,227	0	Feb 21 06:46 PM
Albers Jeffrey W.	Director	Feb 20 '24	Sale	39.07	615	24,031	0	Feb 21 06:46 PM
Gollob Jared	Chief Medical Officer	Feb 09 '24	Option Exercise	2.08	46,137	95,965	120,846	Feb 09 07:47 PM
Gollob Jared	Chief Medical Officer	Feb 09 '24	Sale	35.50	46,137	1,638,071	74,709	Feb 09 07:47 PM
Albers Jeffrey W.	Director	Jan 23 '24	Option Exercise	10.34	10,000	103,400	10,000	Jan 23 07:37 PM
Albers Jeffrey W.	Director	Jan 23 '24	Sale	30.05	10,000	300,470	0	Jan 23 07:37 PM
Chiniara Ellen	Chief Legal Officer	Jan 04 '24	Sale	22.58	3,295	74,416	34,205	Jan 05 05:15 PM
Mainolfi Nello	Chief Executive Officer	Jan 02 '24	Option Exercise	2.08	9,000	18,720	615,570	Jan 02 05:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KYMR

Kymera Therapeutics Inc

Upgrade your FINVIZ experience